Objective:To investigate the relationship among Pokemon,NF-κB p65 and Bcl-2 in hepatoma cells.Methods:HCC cell HepG2,SMMC7721 and human fetal liver cell line L02 cells were used,and expression of Pokemon,NF-κB p65 a...Objective:To investigate the relationship among Pokemon,NF-κB p65 and Bcl-2 in hepatoma cells.Methods:HCC cell HepG2,SMMC7721 and human fetal liver cell line L02 cells were used,and expression of Pokemon,NF-κB p65 and Bcl-2 in three cells were detected by realtime PCR and western blot.Then siRNA of Pokemon was applied to inhibit the expression of Pokemon and NF-κB p65 and apoptotic rate was determined by flow cytometric analysis. Results:Expressions of Pokemon,NF-κB p65 and Bcl-2 in human hepatoma cell HepG2, SMMC7721 expression were significantly higher than those in human embryonic stem cells L02. siRNA of Pokemon inhibited the expression of Pokemon,NF-κB p65 and Bcl-2 in liver cancer cells,and significantly increased apoptosis of liver cells.While siRNA of NF-κB n65 inhibited the expression of NF-κB p65 and Bcl-2,but Pokemon expression in hepatoma cells had no significant change.Conclusions:The proto-oncogene Pokemon can inhibit PI4ARF by specific transcription regulation of cell cycle and can induce tumors.In addition,Pokemon can regulate NF-κB p65 through the expression of apoptosis repressor,and promote the development of liver cancer.It suggests signal network in the liver include the regulation of new non-classical NF-κB regulatory pathway.展开更多
目的探讨弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)组织核转录因子κB(nuclear factor-kappa B,NF-κB)/p65、Bcl-2和Bax蛋白表达及其对临床B症状、国际预后指数(international prognostic index,IPI)得分、临床分期...目的探讨弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)组织核转录因子κB(nuclear factor-kappa B,NF-κB)/p65、Bcl-2和Bax蛋白表达及其对临床B症状、国际预后指数(international prognostic index,IPI)得分、临床分期等病理特征和预后的影响。方法组织标本来自于2012年3月至2015年2月我院接受手术治疗的78例DLBCL患者和30例反应增生性淋巴结患者,采用免疫组化方法比较DLBCL患者和反应增生性淋巴结患者淋巴组织NF-κB/p65、Bcl-2和Bax蛋白表达情况,分析它们与病理参数、生存期的关系。结果 DLBCL组织中,NF-κB/p65和Bcl-2阳性率分别为39.74%和51.28%,显著高于反应增生性淋巴结组织(P<0.05),Bax阳性率为32.05%,显著低于反应增生性淋巴结组织(P<0.05);DLBCL组织NF-κB/p65阳性表达与B症状、IPI得分、临床分期有关(P<0.05),Bcl-2阳性表达与IPI得分、临床分期有关(P<0.05),Bax阳性表达与临床分期有关(P<0.05);NF-κB/p65与Bcl-2呈正相关(r=0.53,P<0.05),NF-κB/p65与Bax呈负相关(r=-0.51,P<0.05),Bcl-2与Bax呈负相关(r=-0.62,P<0.05);NF-κB/p65、Bcl-2阳性表达者生存期较短,Bax阳性表达者生存期较长。结论DLBCL组织中NF-κB/p65、Bcl-2高表达,Bax低表达,有助于DLBCL预后评估。展开更多
文摘Objective:To investigate the relationship among Pokemon,NF-κB p65 and Bcl-2 in hepatoma cells.Methods:HCC cell HepG2,SMMC7721 and human fetal liver cell line L02 cells were used,and expression of Pokemon,NF-κB p65 and Bcl-2 in three cells were detected by realtime PCR and western blot.Then siRNA of Pokemon was applied to inhibit the expression of Pokemon and NF-κB p65 and apoptotic rate was determined by flow cytometric analysis. Results:Expressions of Pokemon,NF-κB p65 and Bcl-2 in human hepatoma cell HepG2, SMMC7721 expression were significantly higher than those in human embryonic stem cells L02. siRNA of Pokemon inhibited the expression of Pokemon,NF-κB p65 and Bcl-2 in liver cancer cells,and significantly increased apoptosis of liver cells.While siRNA of NF-κB n65 inhibited the expression of NF-κB p65 and Bcl-2,but Pokemon expression in hepatoma cells had no significant change.Conclusions:The proto-oncogene Pokemon can inhibit PI4ARF by specific transcription regulation of cell cycle and can induce tumors.In addition,Pokemon can regulate NF-κB p65 through the expression of apoptosis repressor,and promote the development of liver cancer.It suggests signal network in the liver include the regulation of new non-classical NF-κB regulatory pathway.
文摘目的探讨弥漫性大B细胞淋巴瘤(diffuse large B cell lymphoma,DLBCL)组织核转录因子κB(nuclear factor-kappa B,NF-κB)/p65、Bcl-2和Bax蛋白表达及其对临床B症状、国际预后指数(international prognostic index,IPI)得分、临床分期等病理特征和预后的影响。方法组织标本来自于2012年3月至2015年2月我院接受手术治疗的78例DLBCL患者和30例反应增生性淋巴结患者,采用免疫组化方法比较DLBCL患者和反应增生性淋巴结患者淋巴组织NF-κB/p65、Bcl-2和Bax蛋白表达情况,分析它们与病理参数、生存期的关系。结果 DLBCL组织中,NF-κB/p65和Bcl-2阳性率分别为39.74%和51.28%,显著高于反应增生性淋巴结组织(P<0.05),Bax阳性率为32.05%,显著低于反应增生性淋巴结组织(P<0.05);DLBCL组织NF-κB/p65阳性表达与B症状、IPI得分、临床分期有关(P<0.05),Bcl-2阳性表达与IPI得分、临床分期有关(P<0.05),Bax阳性表达与临床分期有关(P<0.05);NF-κB/p65与Bcl-2呈正相关(r=0.53,P<0.05),NF-κB/p65与Bax呈负相关(r=-0.51,P<0.05),Bcl-2与Bax呈负相关(r=-0.62,P<0.05);NF-κB/p65、Bcl-2阳性表达者生存期较短,Bax阳性表达者生存期较长。结论DLBCL组织中NF-κB/p65、Bcl-2高表达,Bax低表达,有助于DLBCL预后评估。